REQUIP
LOE ApproachingNDAORALTABLET
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
REQUIP by GSK is non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the d 2 and d 3 dopamine receptor subtypes, binding with higher affinity to d 3 than to d 2 or d 4 receptor subtypes. Approved for signs, symptoms of idiopathic parkinson’s disease, the signs. First approved in 1997.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REQUIP (ropinirole) is a non-ergoline dopamine agonist oral tablet approved in 1997 for treating signs and symptoms of idiopathic Parkinson's disease. It works by stimulating postsynaptic dopamine D2-type receptors in the brain, with higher affinity for D3 receptors, improving motor function in Parkinson's patients.
LOE Approaching
As REQUIP approaches loss of exclusivity with moderate competitive pressure (30% intensity), the brand team is likely consolidating around market defense and managed transition strategies.
Mechanism of Action
non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D 2 and D 3 dopamine receptor subtypes, binding with higher affinity to D 3 than to D 2 or D 4 receptor subtypes. Ropinirole has moderate in vitro affinity for opioid receptors. Ropinirole and…
Indications (3)
Worked on REQUIP at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.